Minapharm Pharmaceuticals results, Q1 2024
Net profit, assets, equity and cash flow for Q1 2024, against the same period a year earlier, from the published financial statements.
Net profit4.05 millionEGP · −91.9% vs the same period a year earlier
Total assets11.11 billionEGP · +36.7% vs the same period a year earlier
Shareholders' equity4.19 billionEGP · +23.2% vs the same period a year earlier
Operating cash flow132 millionEGP · −5.1% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q1 2024 was about 4.05 million EGP, down −91.9% from 49.93 million EGP in Q1 2023.
- Total assets at the end of Q1 2024 were about 11.11 billion EGP, and shareholders' equity about 4.19 billion EGP.
- Operating cash flow for Q1 2024 was positive at 132 million EGP.
Key lines against the same period a year earlier
This periodQ1 2023Change
Net profit4.05 million49.93 million−91.9%
Gross profit273 million340 million−19.7%
Total assets11.11 billion8.12 billion+36.7%
Total liabilities6.92 billion4.72 billion+46.5%
Shareholders' equity4.19 billion3.4 billion+23.2%
Total liabilities and equity11.11 billion8.12 billion+36.7%
Operating cash flow132 million139 million−5.1%
Investing cash flow-177 million-589 million+70.0%
Financing cash flow1.45 billion569 million+155.2%
Net change in cash1.41 billion119 million+1082.5%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy